POL6014 is an investigational, highly potent, and reversible inhibitor of human neutrophil elastase (hNE). The experimental therapy can be formulated as an aerosol or dry powder formulation as a treatment for lung inflammation in cystic fibrosis (CF) patients.

Neutrophil elastase is a type of protein associated with inflammation in the lungs. Blocking the function of neutrophil elastase can minimize tissue destruction and decrease of inflammation within the airway of people with CF.

How POL6014 works

Human neutrophil elastase (hNE) is a key target for the treatment of respiratory conditions such as CF, chronic obstructive pulmonary disease (COPD), and alpha-1-antitrypsin deficiency (AATD). POL6014 is a selective and reversible inhibitor of hNE.

CF is characterized viscous secretions and bacterial lung inflammation that is dominated by neutrophils. These neutrophils become active and eventually die, liberating enzymes (proteases) that cause damage to structural, cellular and soluble components of the pulmonary environment. The neutrophil elastase enzyme is the most prominent protease released in the lungs of people with cystic fibrosis, playing a key role in the disease.

POL6014 studies

Preclinical pharmacological studies have shown that the aggressive and tissue degrading enzyme neutrophil elastase is inhibited by Polyphor’s POL6014 therapy candidate. It has shown high efficacy in animal models with respiratory diseases.

After inhalation, POL6014 reaches high concentrations in the lungs with a low blood concentration, reducing the risk of side-effects.

Exploratory toxicology studies suggest that POL6014 is well tolerated and safe when chronically inhaled as an aerosol.

POL6014 is still in Phase 1 clinical development.

Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Lonodelestat Safely Blocks Inflammatory Marker in CF Patients in Early Trial

Lonodelestat (also known as POL6014), Santhera Pharmaceuticals’ investigational therapy to treat chronic lung inflammation, was safe and effective at blocking the activity of a pro-inflammatory biomarker in patients with cystic fibrosis (CF), according to data from a Phase 1b trial. “We are very much encouraged by the trial results which support the hypothesis that lonodelestat […]

Safety, Early Effectiveness of POL6014 Confirmed in Phase 1 Trial

Single dosing of orally inhaled POL6014, an experimental therapy to treat chronic lung inflammation, can effectively block the activity of a pro-inflammatory enzyme in the lungs of people with cystic fibrosis (CF), results from a Phase 1 clinical trial show. The data were published in the Journal of Cystic Fibrosis in the study, “Single dose […]

Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014

A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently launched, according to Santhera Pharmaceuticals, developer of the investigational therapy.  The Phase 1b/2a (EudraCT 2016-005110-22) will evaluate the safety, tolerability, pharmacokinetics (drug absorption, distribution, and elimination by the body), and pharmacodynamics (the drug’s effects) of orally inhaled […]

Santhera’s Potential CF Inhalation Therapy Favored for Orphan Drug Status in EU

Santhera Pharmaceuticals’ investigative inhalation therapy for cystic fibrosis (CF), POL6014, has been favored for orphan drug designation within the European Union. A recommendation supporting the designation, which offers financial and regulatory incentives to develop treatments for rare diseases, was made by  Committee for Orphan Medicinal Products (COMP), a branch of the European Medicines Agency (EMA). The positive opinion is […]

Santhera to Develop, Market Polyphor Experimental CF Therapy

Santhera Pharmaceuticals has bought the rights to POL6014, a medication being developed by Polyphor to treat cystic fibrosis (CF) and other pulmonary diseases. Under terms of the global licensing agreement between the two Swiss companies, Santhera will develop, handle regulatory filings and market the investigative drug and derivate compounds. Supported by positive preclinical and clinical data, […]

Promising Phase 1Trial on POL6014 for Cystic Fibrosis Finished

Swiss Pharmaceutical company Polyphor has successfully completed its Phase I clinical trial in healthy volunteers for the investigational inhaled POL6014. POL6014 is a selective and reversible inhibitor of human neutrophil elastase (hNE), a key target for the treatment of respiratory diseases like cystic fibrosis (CF). Cystic fibrosis is a genetic disease in which the lungs and digestive system can […]